OTCMKTS:VVUSQ VIVUS (VVUSQ) Stock Price, News & Analysis → The Key to this $10 Trillion Tech Boom (From Porter & Company) (Ad) Free VVUSQ Stock Alerts $0.12 0.00 (0.00%) (As of 12/17/2020) Add Compare Share Share Today's Range$0.12▼$0.1250-Day Range$0.12▼$0.1252-Week Range$0.07▼$4.55VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get VIVUS alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About VIVUS Stock (OTCMKTS:VVUSQ)VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More VVUSQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVUSQ Stock News HeadlinesMay 14, 2024 | msn.comPorsche's Hybrid 911 Is Finally Coming After 3 Million Miles Of TestingMay 13, 2024 | msn.comPorsche is debuting a new hybrid 911 sports carMay 13, 2024 | msn.comHybrid 911 Coming 2025, but Ferdinand Porsche Invented World's First Hybrid in 1899April 24, 2024 | yahoo.comFerdinand Porsche’s Gas-Electric Hybrid TanksApril 22, 2024 | finance.yahoo.comVIVUS Announces it will Provide Telehealth to Patients through an Enhanced 'Engage' Program in Collaboration with UpScriptHealthApril 12, 2024 | uk.finance.yahoo.comAnti-obesity Drugs market is estimated to grow at a CAGR of 21.2% by 2034: VisiongainFebruary 28, 2024 | msn.comUS pharma giant Eli Lilly plans to introduce its blockbuster anti-diabetes drug Mounjaro to India next year, to target weight loss marketFebruary 9, 2024 | msn.comWeight-loss drugs for teens are controversial. A 16-year-old taking Wegovy shares her storyJanuary 27, 2024 | msn.comThe First Porsche With All-Wheel Drive Was An Off-Road Military VehicleJanuary 5, 2024 | msn.comNorovirus, aka stomach flu, on the rise in the US: Know these signsDecember 30, 2023 | bbc.co.ukGustav Mahler: Eighth Symphony: Part TwoDecember 23, 2023 | msn.comWhy pharma majors are rushing to put anti-obesity drugs on Indian shelvesDecember 14, 2023 | finance.yahoo.comErectile Dysfunction (ED) Drugs Market to grow by USD 1.44 billion from 2023-2028, North America to account for 41% of market growth - TechnavioDecember 7, 2023 | ca.news.yahoo.comCaledon residents donate $500,000 to Headwaters Health Care FoundationDecember 7, 2023 | ca.sports.yahoo.comWhat Is Barre? Everything to Know About This Low-Impact, High-Intensity WorkoutDecember 7, 2023 | ca.sports.yahoo.comTeens who use phones for over 4 hours daily face higher health risks: studyDecember 7, 2023 | ca.sports.yahoo.comCharlotte hospitals change visitor guidelines due to rising COVID-19, flu and RSV casesDecember 7, 2023 | ca.news.yahoo.comHospital Pushed Weight-Loss Surgery on Prisoners Who Recovered in Jail: NYTDecember 6, 2023 | ca.sports.yahoo.comFree at-home testing and treatments now available for COVID and flu through federal programDecember 6, 2023 | ca.news.yahoo.comSaskatchewan auditor reports longer waits for neurosurgeries; more homelessnessDecember 6, 2023 | ca.sports.yahoo.comBoris Johnson admits he should 'twigged the risk' of Covid earlierDecember 6, 2023 | ca.news.yahoo.comThis Is How I Finally Got My Tubes Removed After Years Of Doctors Fighting Me On ItDecember 6, 2023 | reuters.comAdherence to weight-loss drugs is far higher with Wegovy than older medicinesOctober 3, 2023 | finance.yahoo.comAnti-Obesity Drugs Market is forecasted to reach USD 8.2 billion by 2032, growing at a 14.6% CAGR from 2023 to 2032September 28, 2023 | reuters.comWegovy, other weight-loss drugs scrutinized over reports of suicidal thoughtsSee More Headlines Receive VVUSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:VVUSQ CUSIPN/A CIKN/A Webwww.vivus.com Phone650-934-5200Fax650-934-5389Employees59Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. John P. Amos (Age 53)CEO, Pres & Director Comp: $556.2kMr. Mark K. Oki (Age 51)Sr. VP, CFO & Chief Accounting Officer Comp: $422.2kMr. John L. Slebir (Age 55)Sr. VP of Bus. Devel., Gen. Counsel & Sec. Comp: $632.7kDr. Santosh T. Varghese (Age 50)Sr. VP & Chief Medical Officer Comp: $555.44kMs. Deborah LarsenChief Strategy Officer - Commercial OperationsKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors VVUSQ Stock Analysis - Frequently Asked Questions How have VVUSQ shares performed in 2024? VIVUS's stock was trading at $0.1174 at the start of the year. Since then, VVUSQ shares have increased by 0.0% and is now trading at $0.1174. View the best growth stocks for 2024 here. How do I buy shares of VIVUS? Shares of VVUSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VVUSQ) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VIVUS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.